Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$0.32 USD
0.00 (1.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.32 0.00 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Lyra Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -62.68 | -55.28 | -43.51 | -22.13 | -16.31 |
Depreciation/Amortization & Depletion | -3.22 | 0.58 | 1.00 | 0.10 | 0.03 |
Net Change from Assets/Liabilities | -4.89 | 4.56 | 13.92 | -0.88 | 2.11 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.48 | 6.76 | 2.77 | 1.77 | 0.41 |
Net Cash From Operating Activities | -63.30 | -43.39 | -25.82 | -21.14 | -13.75 |
Property & Equipment | -1.05 | -0.16 | -3.39 | -1.78 | -0.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -11.54 | -64.84 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -12.58 | -65.01 | -3.39 | -1.78 | -0.21 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 69.35 | 100.50 | 0.60 | 90.29 | 0.11 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -3.65 | -4.25 | -0.25 | -2.59 | -0.23 |
Net Cash from Financing Activities | 65.69 | 96.26 | 0.36 | 87.70 | -0.12 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -10.20 | -12.13 | -28.85 | 64.79 | -14.08 |
Cash at Beginning of Period | 33.94 | 46.08 | 74.92 | 10.14 | 24.22 |
Cash at End of Period | 23.75 | 33.94 | 46.08 | 74.92 | 10.14 |
Diluted Net EPS | -1.26 | -1.83 | -3.35 | -2.59 | NA |
Fiscal Year End for Lyra Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -70.58 | -22.45 | -62.68 | -47.52 | -31.87 |
Depreciation/Amortization & Depletion | -1.33 | -0.80 | -3.22 | -2.22 | -1.09 |
Net Change from Assets/Liabilities | 1.33 | -1.37 | -4.89 | -0.50 | -1.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 28.15 | 2.16 | 7.48 | 6.00 | 4.56 |
Net Cash From Operating Activities | -42.44 | -22.46 | -63.30 | -44.25 | -30.13 |
Property & Equipment | -2.35 | -2.15 | -1.05 | -0.26 | -0.12 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 46.38 | 10.01 | -11.54 | -9.96 | 4.87 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 44.03 | 7.86 | -12.58 | -10.23 | 4.75 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.82 | 8.81 | 69.35 | 50.10 | 50.10 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.27 | -0.17 | -3.65 | -3.33 | -2.91 |
Net Cash from Financing Activities | 8.56 | 8.64 | 65.69 | 46.77 | 47.19 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 10.15 | -5.95 | -10.20 | -7.70 | 21.81 |
Cash at Beginning of Period | 23.75 | 23.75 | 33.94 | 33.94 | 33.94 |
Cash at End of Period | 33.90 | 17.79 | 23.75 | 26.24 | 55.75 |
Diluted Net EPS | -0.74 | -0.35 | -0.19 | -0.27 | -0.36 |